Search Results

Daicel Arbor Biosciences is excited to announce the release of the next generation of its myTXTL® kits, for cell-free protein expression, designed to simplify and accelerate antibody discovery and protein engineering.

Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies.

The life science group Sartorius opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, two years after breaking ground in the Tech Loop at Research Park.

Blue Arbor Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the RESTORE™ Neuromuscular Interface System for people with upper limb loss.

Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).

Allogene Therapeutics and Arbor Biotechnologies will use their allogeneic CAR T and next-generation gene-editing platforms to develop novel off-the-shelf CAR-T therapies for autoimmune diseases.

Arbor today announced a collaboration with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to leverage Ginkgo’s comprehensive Codebase and automated Foundry to jointly optimize Arbor’s novel precision editors.

Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced four upcoming presentations at the 2024 American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place May 7-11 in Baltimore, Maryland.

Arbor Biotechnologies® presents preclinical data demonstrating the potential of ABO-101, its novel gene editing therapeutic designed to address primary hyperoxaluria type 1, as well as its broader discovery capabilities and their application to enable novel gene editing therapeutics in a suite of presentations at the 2024 American Society of Gene and Cell Therapy 27th Annual Meeting in Baltimore, Maryland.